Please assess the completion status of the following clinical trial:

Trial Title: Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of prostate cancer~* Demonstrates metastatic CRPC~* Castrate level of serum testosterone at screening~* Adequate hematologic, renal, and hepatic function~* ECOG status ≤1~* Life expectancy of at least 3 months~* No more than one prior course of cytotoxic chemotherapy~Exclusion Criteria:~* Pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histology~* Visceral metastasis excluding lymph nodes~* Use of opiate analgesics for prostate cancer pain or non-cancer pain~* other investigational agents or concurrent anticancer therapy other than standard androgen deprivation therapy within 4 weeks~* History of bleeding disorder~* History of seizure disorder~* Concomitant use of warfarin~* Prior exposure to PCUR-101~* History of myocardial infarction, arterial thrombotic events, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia~* Received wide-field external beam radiation therapy within 4 weeks~* Moderate to severe neuropathy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCUR-101 Dose Escalation (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in 28 day cycles. Patients will be enrolled into escalating dose levels during the dose escalation phase
- PCUR-101 Dose Expansion Cohort 1 (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in 28 day cycles
- PCUR-101 Dose Expansion Cohort 2 (Type: EXPERIMENTAL): PCUR-101 in combination with dutasteride dosed orally once per day in 28 day cycles
- PCUR-101 Dose Expansion Cohort 3 (Type: EXPERIMENTAL): PCUR-101 dosed orally once per day in combination with abiraterone (once per day) and prednisone (twice per day) in 28 day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).